The White House has withdrawn Dr. Heidi Overton’s nomination to lead the Food and Drug Administration. The Senate Health, Education, Labor and Pensions Committee had been scheduled to vote Wednesday on Overton, President Trump’s pick for FDA commissioner.
Overton, a physician and White House domestic policy staffer, had struggled to build support among Senate Republicans. Some lawmakers and administration allies questioned her nomination in part because of her testimony regarding the FDA-approved abortion drug mifepristone and her execution of Trump’s pro-vape policies.
Sen. Bill Cassidy of Louisiana, the outgoing chair of the Senate HELP Committee, said late Tuesday that the issue was not a lack of votes. He said the “White House abandoned a viable confirmation path.” Cassidy said “pro-life Senators sought final assurances from the Administration regarding the Administration’s commitment to life issues,” but the administration withdrew Overton instead.
The FDA regulates products that account for about 20% of US consumer spending. The agency has not had a Senate-confirmed leader since Dr. Marty Makary was forced out in May. Acting Commissioner Kyle Diamantas is currently running the agency.
The decision leaves the administration with little time to confirm a permanent FDA commissioner before Democrats take control of the Senate in January. Cassidy warned that “with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats.”




